Preferred Label : Decitabine and Cedazuridine;
NCIt synonyms : Cedazuridine/Decitabine Tablet; CDA Inhibitor E7727/Decitabine Combination Agent ASTX727; Cedazuridine/Decitabine Combination Agent ASTX727; DEC-C; C-DEC;
NCIt definition : An orally available fixed-dose combination agent containing cedazuridine, a cytidine
deaminase (CDA) inhibitor, and the cytidine antimetabolite decitabine, with potential
antineoplastic activity. Upon oral administration of tdecitabine and cedazuridine,
cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal
(GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs.
This prevents the breakdown of decitabine, increases its bioavailability and efficacy
while decreasing GI toxicity due to the administration of lower doses of decitabine.
Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate
form into DNA, which inhibits DNA methyltransferase and results in hypomethylation
of DNA. This interferes with DNA replication and decreases tumor cell growth.;
Drug name : Inqovi;
Molecule name : ASTX727;
NCI Metathesaurus CUI : CL472633;
Codes from synonyms : 14235;
Origin ID : C115102;
UMLS CUI : C5390939;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/inqovi-5667.html
2021
false
false
false
Canada
French
administration, oral
Product containing precisely cedazuridine 100 milligram and decitabine 35 milligram/1
each conventional release oral tablet (clinical drug)
drug evaluation
quebec
drug combinations
Decitabine
antimetabolites, antineoplastic
Decitabine and Cedazuridine
myelodysplastic syndromes
leukemia, myelomonocytic, chronic
decitabine and cedazuridine drug combination
decitabine, combinations
---
